

Innovative Microphysiological Model Using HepatoXcellTM **Primary Human Hepatocytes and Locsense Artemis**

Eline K. Geervliet, PhD;¹ Marit Zuurveld, PhD;² Brian Shapiro, PhD;³ Sopheap Sun, MBA;³ Parth Patel, MS;¹ Ruby E. Thamert, MS;³ Emma Todd, BS;³ Susan H. Roelofs, PhD;¹ and Sujoy Lahiri, PhD³ ¹Locsense B.V., Enschede, Netherlands; ²Utrecht University, Utrecht, Netherlands; and ³ATCC[®], Manassas, VA

1. Introduction

The development of a highly representative in vitro gut-liver model is essential for improving drug testing accuracy while minimizing the reliance on animal studies. Traditional animal models often fail to fully replicate human physiology, leading to discrepancies in drug metabolism and toxicity predictions.¹ A physiologically relevant gut-liver system would provide a more accurate platform to study nutrient absorption, drug bioavailability, and toxicity, ultimately enhancing preclinical research. This approach aligns with the 3Rs principle (Replacement, Reduction, and Refinement), promoting ethical and sustainable alternatives to animal testing while advancing biomedical research and drug development.




Figure 1: Gut-liver axis interaction

2. Background

The gut-liver axis represents a bidirectional communication network between the gastrointestinal (GI) tract and the liver, playing a pivotal role in metabolism, immunity, and detoxification. This connection is primarily facilitated by the portal vein, which transports nutrients, metabolites, microbial products, and toxins from the gut to the liver for processing. To develop a highly representative model, the selection of cellular components is critical. Caco-2 cells are ideal candidates for an invitro intestinal barrier model as they spontaneously differentiate into polarized, enterocyte-like cells, forming tight junctions that mimic the intestinal epithelium. HepatoXcell primary human hepatocytes are excellent candidates for an in vitro liver model due to their retention of key liver-specific functions. These cells can provide early insights into drug behavior in the human body, potentially reducing the risk of adverse effects in clinical trials. **Figure 2** illustrates the morphology and fluorescent expression of key markers in the primary hepatocytes.






Figure 2: HepatoXcell. (A) Phase contrast image (20x) of HepatoXcell Pro cells plated in collagen I-coated plates in sandwich culture. (B) HepatoXcell Pro cells imaged at 10x magnification following staining with 5(6)-Carboxyfluorescein diacetate (CDFDA), demonstrating bile accumulation in the bile ducts (green). (C) HepatoXcell Pro cells on day 5 of culture were imaged at 10x magnification under a fluorescent microscope following staining with E-Cadherin (green) and Occludin (red) antibodies, illustrating cell-cell adhesion and epithelial tight junctions, respectively. The nuclei were counterstained with DAPI (blue).

3. Aims

Development of a highly representative in vitro gut-liver model using Caco-2 gut epithelial cells and HepatoXcell primary human hepatocytes to reduce the burden of animal testing



2. Co-culture






Figure 5: Schematic overview of impedance set up. The smart lid fit a 12-well plate and can measure the impedance and phase data of 12 wells in several minutes. These data are transferred to the laptop which performs CMF to extract TEER data.

Figure 7. TEER and viability WST-1. (A) TEER over time of the Caco-2 intestinal barrier. (B) Relative viability of Caco-2 cells under PBS and/or 2 µg/mL LPS-induced stress compared to Caco-2 cells in control medium. (C) Relative viability of hepatocytes in coculture with Caco-2 cells under stress compared to hepatocytes in mono-culture.

E. Todd

of Corning Incorporated

Abstract #5186

Poster #LB287

8. Author information

S. Sun

S. H. Roelofs

S. Lahiri

HepatoXcell, HTB-37, PCS-450-011, and ATCC are trademarks or registered trademarks of American Type Culture Collection. Transwell is a registered trademark